Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diphosphonate bone scanning agents--current concepts.

I Fogelman

    European Journal of Nuclear Medicine
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    New bone scanning agents offer higher skeletal uptake but do not improve lesion detection compared to technetium-99m-methylene diphosphonate. Further research is needed to determine the ideal properties for bone scanning agents in skeletal disease evaluation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.

    The journal of prevention of Alzheimer's disease·2017
    Same author

    Correction to: 18F-NaF PET/CT: EANM procedure guidelines for bone imaging.

    European journal of nuclear medicine and molecular imaging·2017
    Same author

    Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting.

    Clinical endocrinology·2015
    Same author

    Circulating concentrations of vitamin E isomers: Association with bone turnover and arterial stiffness in post-menopausal women.

    Bone·2015
    Same author

    (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging.

    European journal of nuclear medicine and molecular imaging·2015
    Same author

    The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.

    Cytokine·2014
    Same journal

    [Not Available].

    European journal of nuclear medicine·2016
    Same journal

    A Window on Latin America.

    European journal of nuclear medicine·2016
    Same journal

    Erratum: Eur J Nucl Med (1999) 26: 686-692.

    European journal of nuclear medicine·2016
    Same journal

    Nuclear medicine in the next decade.

    European journal of nuclear medicine·2014
    Same journal

    Erratum: Impact of attenuation correction on the accuracy of FDG-PET in patients with abdominal tumors: a free-response ROC analysis.

    European journal of nuclear medicine·2014
    Same journal

    (99m)Tc(V)DMSA quantitatively predicts (188)Re(V)DMSA distribution in patients with prostate cancer metastatic to bone.

    European journal of nuclear medicine·2014
    See all related articles

    Area of Science:

    • Nuclear Medicine
    • Radiopharmacology
    • Skeletal Imaging

    Background:

    • Bone scintigraphy is a crucial tool for diagnosing skeletal diseases.
    • Technetium-99m-methylene diphosphonate (99mTc-MDP) is the standard bone scanning agent.
    • New diphosphonate compounds exhibit increased skeletal affinity and tracer uptake.

    Purpose of the Study:

    • To review clinical studies of diphosphonate bone scanning agents.
    • To discuss the properties of an ideal bone scanning agent for skeletal disease.
    • To evaluate if increased tracer uptake improves disease detection.

    Main Methods:

    • Literature review of clinical studies comparing diphosphonate bone scanning agents.
    • Analysis of tracer uptake and skeletal affinity.

    Related Experiment Videos

  • Assessment of lesion detection rates in benign and malignant skeletal diseases.

    • Main Results:

    • Newer diphosphonate agents show higher bone uptake and improved contrast.
    • No significant difference in lesion detection has been observed between different diphosphonate compounds.
    • The clinical benefit of increased bone uptake for disease identification remains unclear.

    Conclusions:

    • While new agents enhance image quality, their superiority in disease detection over 99mTc-MDP is not established.
    • The ideal bone scanning agent should balance high skeletal uptake with effective lesion visualization.
    • Further investigation is required to define optimal properties for bone scanning agents in evaluating skeletal pathologies.